X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs CIPLA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA CIPLA ABBOTT INDIA/
CIPLA
 
P/E (TTM) x 36.7 34.4 106.6% View Chart
P/BV x 9.4 3.0 314.8% View Chart
Dividend Yield % 0.7 0.6 129.4%  

Financials

 ABBOTT INDIA   CIPLA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
CIPLA
Mar-18
ABBOTT INDIA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs6,110663 921.6%   
Low Rs3,996479 834.2%   
Sales per share (Unadj.) Rs1,552.2189.0 821.2%  
Earnings per share (Unadj.) Rs188.817.6 1,073.1%  
Cash flow per share (Unadj.) Rs196.434.0 577.3%  
Dividends per share (Unadj.) Rs55.003.00 1,833.3%  
Dividend yield (eoy) %1.10.5 207.2%  
Book value per share (Unadj.) Rs796.6176.7 450.7%  
Shares outstanding (eoy) m21.25805.12 2.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.33.0 107.8%   
Avg P/E ratio x26.832.5 82.5%  
P/CF ratio (eoy) x25.716.8 153.3%  
Price / Book Value ratio x6.33.2 196.3%  
Dividend payout %29.117.1 170.8%   
Avg Mkt Cap Rs m107,376459,724 23.4%   
No. of employees `0003.323.6 14.1%   
Total wages/salary Rs m3,93726,901 14.6%   
Avg. sales/employee Rs Th9,929.36,446.1 154.0%   
Avg. wages/employee Rs Th1,185.11,139.4 104.0%   
Avg. net profit/employee Rs Th1,207.7600.0 201.3%   
INCOME DATA
Net Sales Rs m32,985152,193 21.7%  
Other income Rs m1,1703,577 32.7%   
Total revenues Rs m34,155155,769 21.9%   
Gross profit Rs m5,24528,264 18.6%  
Depreciation Rs m16213,228 1.2%   
Interest Rs m381,142 3.3%   
Profit before tax Rs m6,21517,470 35.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m2,2032,501 88.1%   
Profit after tax Rs m4,01214,166 28.3%  
Gross profit margin %15.918.6 85.6%  
Effective tax rate %35.414.3 247.6%   
Net profit margin %12.29.3 130.7%  
BALANCE SHEET DATA
Current assets Rs m22,655108,141 20.9%   
Current liabilities Rs m6,68138,322 17.4%   
Net working cap to sales %48.445.9 105.6%  
Current ratio x3.42.8 120.2%  
Inventory Days Days6597 66.8%  
Debtors Days Days2974 39.2%  
Net fixed assets Rs m835109,411 0.8%   
Share capital Rs m2131,610 13.2%   
"Free" reserves Rs m16,715140,682 11.9%   
Net worth Rs m16,928142,292 11.9%   
Long term debt Rs m036,621 0.0%   
Total assets Rs m24,162228,606 10.6%  
Interest coverage x163.716.3 1,004.6%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.40.7 205.1%   
Return on assets %16.86.7 250.3%  
Return on equity %23.710.0 238.1%  
Return on capital %36.910.0 371.1%  
Exports to sales %032.8 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA49,883 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36951,691 0.7%   
Fx outflow Rs m3,80721,033 18.1%   
Net fx Rs m-3,43830,658 -11.2%   
CASH FLOW
From Operations Rs m1,52714,628 10.4%  
From Investments Rs m-2,148-8,540 25.2%  
From Financial Activity Rs m-1,024-3,855 26.6%  
Net Cashflow Rs m-1,6462,431 -67.7%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 75.0 20.8 360.6%  
Indian inst/Mut Fund % 7.9 12.2 64.8%  
FIIs % 0.1 23.7 0.4%  
ADR/GDR % 0.0 1.1 -  
Free float % 17.1 26.2 65.3%  
Shareholders   18,270 161,166 11.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   PIRAMAL ENTERPRISES  GSK PHARMA  PANACEA BIOTECH  MERCK LTD  JUBILANT LIFE SCIENCES  

Compare ABBOTT INDIA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 629 Points Higher; Realty and Auto Stocks Witness Buying(Closing)

Indian share markets continued their momentum throughout the day and ended the day on a strong note. Gains were largely seen in the realty sector, telecom sector and auto sector.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Dec 12, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS